Drugs for Neglected Diseases Initiative India

Recent papers from Drugs for Neglected Diseases Initiative India

1. Agreement Between Venous and Capillary Haemoglobin Concentrations in a High-Burden Urban Indian Setting: A Cross-Sectional AnalysisDiagnostics · 2026
2. ICH E21: from landmark guidance to specific action for maternal and child healthJournal of Translational Medicine · 2026
3. A Phase IIa, Proof-of-Concept, Placebo-Controlled, Randomised Trial to Investigate the Efficacy and Safety of Oxfendazole as a Macrofilaricidal Drug in Adults Harbouring Lymphatic Filarial WormsInfectious Diseases and Therapy · 2026
4. Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasisInternational Journal of Antimicrobial Agents · 2026
5. Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal DosingClinical Pharmacology & Therapeutics · 2025
6. Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitisClinical and Translational Science · 2024
7. Paving the way for affordable and equitable liposomal amphotericin B access worldwideThe Lancet Global Health · 2024
8. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and BangladeshPLoS neglected tropical diseases · 2024
9. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South AsiaJournal of Antimicrobial Chemotherapy · 2024
10. Visceral leishmaniasis in the hills of western Nepal: A transmission assessmentPLoS ONE · 2024
11. Leveraging mRNA Platform Technology to Accelerate Development of Vaccines for Some Emerging and Neglected Tropical Diseases Through Local Vaccine ProductionFrontiers in Tropical Diseases · 2022
12. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, IndiaPLoS neglected tropical diseases · 2020
13. Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14–16 May 2018Parasites & Vectors · 2020
14. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported dataPLoS neglected tropical diseases · 2020
15. Impact of the visceral leishmaniasis elimination initiative on Leishmania donovani transmission in Nepal: a 10-year repeat surveyThe Lancet Global Health · 2020
16. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, IndiaPLoS neglected tropical diseases · 2019
17. Innovations for the elimination and control of visceral leishmaniasisPLoS neglected tropical diseases · 2019
18. Eliminating visceral leishmaniasis in South Asia: the road aheadBMJ · 2019
19. Innovation is vital for elimination of neglected diseases in South AsiaBMJ · 2019
20. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.PLoS neglected tropical diseases · 2017